| Abstract [eng] |
Psychopharmacology is an important and effective way of therapy in treatment of many mental health disorders and their symptoms. Depression is one of the most common mental health disorders, and treatment with antidepressants is one of the principal methods of its treatment. However, it is known, that only 25 % to 60 % of medical treatment is successful when using standard doses of medications. CYP450 enzyme activity is responsible for drug metabolism and is one of the most important determinants of drug effectiveness. Activity of these enzymes is dependant on the genotype and its polymorphisms. The aim of this work is to determine CYP2D6 and CYP2C19 genes polymorphisms influence on the clinical antidepressant efficacy when treating Lithuanian patients with moderate and severe depression. The study included 78 patients, the data obtained was compared with the data of 104 people in the control group. After evaluating the influence from CYP2D6 genotype predicted phenotype on treatment responses, it was found that CYP2D6 genes polymorphisms did not affect the clinical antidepressant efficacy or the impact could not be evaluated statistically due to the very unequal sample sizes. After assessing the influence from CYP2C19 genotype predicted phenotype, it was found that CYP2C19 genes polymorphisms did affect clinical antidepressant efficacy: patients who had altered metabolism recovered more slowly, experienced statistically significantly more and more severe symptoms of depression. Results of genetic tests do not change throughout a person's lifetime, therefore obtained genetic information remains relevant not only in retrospective assessment of unsuccessful treatment cases but also in the future when applying personalised treatment. |
